EPISODE · Sep 26, 2024 · 49 MIN
EASL Studio Podcast: Is it time to abandon the use of ultrasound for HCC surveillance in MASLD?
from EASL Podcasts · host European Association for the Study of the Liver
This episode explores the latest developments in liver disease, with a focus on metabolic-associated steatotic liver disease (MASLD) and its impact on liver cancer, particularly hepatocellular carcinoma (HCC). The main focus is the emerging role of advanced imaging technologies. The discussion:Compares traditional ultrasound with advanced imaging techniques.Examines AI-based approaches in patient classification.The episode concludes with a forward-looking perspective on the future management of MASLD.FacultyThomas Berg (Moderator)Timm Denecke (Faculty)Juan-Manuel Pericàs (Faculty)Valérie Vilgrain (Faculty)This EASL Studio is supported by Bayer. EASL has received no input from Bayer with regards to the content of this programme.Related episodesEASL Studio at the Congress 2024: MASLD anno 2024: A rapidly changing landscapeEASL Studio S6E1: Do we solve MASLD by treating obesity?EASL Studio S4 Special Edition 1: A new strategy for liver cancer screening: EASL Policy Statement on risk-based surveillanceAll EASL Studio Podcasts are available on EASL Campus.
Embed this episode
What this episode covers
This episode explores the latest developments in liver disease, with a focus on metabolic-associated steatotic liver disease (MASLD) and its impact on liver cancer, particularly hepatocellular carcinoma (HCC). The main focus is the emerging role of advanced imaging technologies. The discussion: Compares traditional ultrasound with advanced imaging techniques.Examines AI-based approaches in patient classification.The episode concludes with a forward-looking perspective on the future management...
NOW PLAYING
EASL Studio Podcast: Is it time to abandon the use of ultrasound for HCC surveillance in MASLD?
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.